{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:32Z","timestamp":1792725212083,"version":"4.5.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Ablative fractional laser treatment facilitates epidermal drug delivery, which might be an interesting option to increase the topical efficacy of biological drugs in a variety of dermatological diseases. This work aims at investigating safety and tolerability of this new treatment approach in patients with plaque-type psoriasis. Eight patients with plaque-type psoriasis were enrolled in this study. All patients received (i) ablative fractional laser microporation (AFL) of a psoriatic lesion with an Er:YAG laser + etanercept (ETA; Enbrel\u00ae solution for injection) (AFL-ETA), (ii) ETA alone on another lesion, and, if feasible, (iii) AFL alone on an additional lesion. Overall, all treatment arms showed a favorable safety profile. AFL-ETA improved the lesion-specific TPSS score by 1.75 vs. baseline, whereas ETA or AFL alone showed a TPSS score improvement of 0.75 points, a difference that was not statistically significant and might be attributable to differences in baseline scores. Topical administration of ETA to psoriatic plaques <jats:italic>via<\/jats:italic> AFL-generated micropores was generally well-tolerated. No special precautions seem necessary in future studies. Clinical benefit will need assessment in sufficiently powered follow-up studies.<\/jats:p>","DOI":"10.3389\/fmed.2021.712511","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:34:16Z","timestamp":1626435256000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis"],"prefix":"10.3389","volume":"8","author":[{"given":"Martin","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Matzneller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Al Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahra","family":"Pajenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"B\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Boesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"adv00033","DOI":"10.2340\/00015555-3387","article-title":"Psoriasis and co-morbidity","volume":"100","author":"Amin","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. paradoxical. the Yin-Yang of TNF and Type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"adv00032","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/exd.12927","article-title":"The single-chain anti-TNF-alpha antibody DLX105 induces clinical and biomarker responses upon local administration in patients with chronic plaque-type psoriasis","volume":"25","author":"Tsianakas","year":"2016","journal-title":"Exp Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s10103-020-02950-2","article-title":"Enhanced topical cutaneous delivery of indocyanine green after various pretreatment regimens: comparison of fractional CO2 laser, fractional Er:YAG laser, microneedling, and radiofrequency","volume":"35","author":"Nieboer","year":"2020","journal-title":"Lasers Med Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejpb.2012.11.018","article-title":"Controlled intra- and transdermal protein delivery using a minimally invasive Erbium:YAG fractional laser ablation technology","volume":"84","author":"Bachhav","year":"2013","journal-title":"Eur J Pharm Biopharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejps.2019.05.007","article-title":"Er:YAG fractional laser ablation for cutaneous co-delivery of pentoxifylline and d-alpha-tocopherol succinate: a new approach for topical treatment of radiation-induced skin fibrosis","volume":"135","author":"Gou","year":"2019","journal-title":"Eur J Pharm Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"119234","DOI":"10.1016\/j.ijpharm.2020.119234","article-title":"Targeted cutaneous delivery of etanercept using Er:YAG fractional laser ablation","volume":"580","author":"Del","year":"2020","journal-title":"Int J Pharm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmi.2020.08.033","article-title":"Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial","volume":"27","author":"Chatzis","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/lsm.22484","article-title":"Fractional laser-assisted drug delivery: laser channel depth influences biodistribution and skin deposition of methotrexate","volume":"48","author":"Taudorf","year":"2016","journal-title":"Lasers Surg Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/17425247.2018.1472570","article-title":"Needle-free cutaneous delivery of living human cells by Er:YAG fractional laser ablation","volume":"15","author":"Yu","year":"2018","journal-title":"Expert Opin Drug Deliv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ophtha.2013.10.037","article-title":"Cost- effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration","volume":"121","author":"Stein","year":"2014","journal-title":"Ophthalmology"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.712511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T11:34:18Z","timestamp":1626435258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.712511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":15,"alternative-id":["10.3389\/fmed.2021.712511"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.712511","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"article-number":"712511"}}